Ringworm Treatment Market
Market Insights on Ringworm Treatment covering sales outlook, demand forecast & up-to-date key trends
Ringworm Treatment Market by Drug Class, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Ringworm Treatment Market Snapshot (2023 to 2033)
The global ringworm treatment market is expected to reach US$ 8.38 Billion in 2023 and is projected to exhibit a CAGR of 5.2% from 2023 to 2033. The high prevalence of skin diseases and the high incidence of ringworm are the major factors driving the global market for ringworm treatments.
A fungal infection of the skin called dermatophytosis is on the rise for antifungal products such as creams, dusting powders, and oral medications. The incidence of ringworm may reach as high as 20% worldwide every year. It is more common for men to contract groin infections, while females are equally likely to contract scalp and body infections. Children are most likely to contract scalp infections, while the elderly are most likely to suffer from groin infections
FMI predicts that by 2023, the drug class segment will account for more than 3/5th of ringworm treatment sales. According to estimates, ultraviolet races will collectively hold more than half of the market share by 2032. Phototherapy utilizing ultraviolet light is highly popular in treating fungus infections on the skin, such as ringworm. Medical professionals in various developed regions use UV light therapy to treat affected skin areas, and the demand for these therapies has increased. Usually, this therapy takes a few weeks to complete in a series of treatments.
|
Data Points |
Key Statistics |
|
Estimated Base Year Value (2022) |
US$ 8 Billion |
|
Expected Market Value (2023) |
US$ 8.38 Billion |
|
Anticipated Forecast Value (2033) |
US$ 13.91 Billion |
|
Projected Growth Rate (2023 to 2033) |
5.2% CAGR |
Let us know your requirement to get
100% FREE customization
2018 to 2022 Ringworm Treatment Market Demand Analysis vs. Forecast 2023 to 2033
The global demand for ringworm treatment is projected to increase at a CAGR of 5.2% during the forecast period between 2023 and 2033, reaching a total of US$ 13.91 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4.7%.
Worldwide awareness of the problem of ringworm among consumers is likely leading to the development of tropical treatments in the market. Natural and homemade remedies are most frequently used by consumers to treat ringworm. In children, tinea capitis caused by Trichophyton species may be treated with griseofulvin and newer treatments including terbinafine, itraconazole, and fluconazole.
Fungal infections are a risk to several children and the growth of these diseases will lead to the development of antifungal treatments. Children with Trichophyton infection may benefit more from griseofulvin than ketoconazole, whereas terbinafine, itraconazole, and fluconazole may have similar effects. There have been studies showing that terbinafine or griseofulvin is effective in curing Trichophyton infections exceeding 90%, but in many comparisons, this proportion is much lower.
What are the Major Market Drivers of Ringworm Treatments?
Growing Incidence of Ringworm Cases to Drive Market Growth
Ringworm is one of the most prevalent skin diseases in the world, contributing to the growth of the global ringworm treatment market. The increased prevalence of bacterial and viral infections, coupled with a rise in awareness about the treatment of fungal infections and the development of novel treatments for diseases, is driving the global market for antifungals to grow.
With the increasing amount of research and development funding and the development of new therapies, the market for ringworm treatment is expected to grow significantly in the coming years. The rise in the number of combination therapies, the increase in the amount of funding allocated to healthcare, and the development of innovative products are also anticipated to drive the global ringworm treatment market. With increasing awareness about the importance of hygiene and the spread of diseases, the market for ringworm treatments will continue to grow.
In recent years, oral and applied product development has been occurring in the market, and the growing concerns associated with these diseases in children have increased market growth. It has also been noted that rapid advancements in nanotechnology for the development of advanced formulations of medications have also played a significant role in the growth of this market.
Advancement in Technology and Drug Development to Expand the Market for Ringworm Treatments
With the advancement of technology and the development of new drugs, there has been a positive impact on the market for ringworm treatments. There has been a significant increase in the effectiveness of treatment for ringworm infection in recent years due to the development of new drugs and improved diagnosis and treatment protocols. An array of new medications has been developed to treat ringworm infections, including antifungal medications and immunomodulators.
As a result of technological advancements like PCR technology, antigen detection kits, and culture tests, it has become easier to diagnose ringworm infections with greater accuracy. The development of new technologies has also made it possible for treatment to be produced and delivered more efficiently, which has resulted in an overall increase in the availability of treatment. In recent years, the development of novel drugs and treatments has made ringworm treatments more accessible to those who are most vulnerable and more affordable, making them available to a broader range of people.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow are Challenges Associated with Ringworm Treatment?
Drugs with a High Incidence of Side Effects and Frequent Use will hamper the Market
There are several factors that are likely to hinder the growth of the antifungal market in the forecast period, including a lack of understanding of the benefits of antifungal medicines in emerging countries, regulatory approval delays, and adverse effects caused by these drugs. Despite the fact that generic drugs are becoming increasingly available for the regular treatment of fungal infections, the cost of these drugs is increasing and thus restricting the market growth. As a consequence of overusing steroids to treat ringworm, there is an increasing risk of developing antimicrobial-resistant ringworm infections.
A rise in the popularity of self-treatments using natural and ayurvedic treatments at home will further impede the growth of the market. A lack of awareness about diseases and proper treatment will present a challenge to the market. In addition to this, the adverse effects caused by the antifungal medicines used for the eradication of fungal infections are also holding the market back from growth. Furthermore, there are also certain important factors that hinder the market during the forecast period, including the existence of rigid government regulations, the expiration of patents and drugs, the rapid emergence of fungicide resistance, as well as the proliferation of counterfeit products.
Region Wise Insights
What is the Outlook for the Ringworm Treatment Market in the Asian Pacific Region?
Increasing Disposable Income and Adoption of Various Treatments Drive Ringworm Treatment
The Asia Pacific region is projected to grow at a CAGR of 3.2% during the forecast period, the fastest growth rate among all regions. According to industry forecasts, the Asia Pacific market will exhibit the fastest growth rate in the coming years. An increase in healthcare expenditures, coupled with an aging population, is expected to drive the growth of fungal infections in this region.
In Asia Pacific, the pharmaceutical industry is experiencing a surge in disposable income, chronic diseases are on the rise, and global companies are focusing on the region. Market growth is expected to continue due to the expansion of international pharmaceutical companies in developing regions and the significant demand for funding for studies in the market for ringworm treatments. Rural areas with a higher prevalence of pet adoption will have a greater likelihood of transmitting the disease, unhealthy living habits, and a higher prevalence of disease transmission rates. With the growing adoption and development of ayurvedic treatments in India, ringworm treatments have grown exponentially.
What is the Projected Growth Rate of the North American Ringworm Treatment Market?
A large number of Pharmaceutical Companies Focusing on Treating Ringworm is in High Demand
Globally, North American markets are forecast to account for 14% of the overall market. According to projections, North America will dominate the global market for ringworm treatments. A growing healthcare sector, an increase in pet ownership, and an increase in awareness regarding skin diseases are a few of the factors driving the demand for ringworm treatments in the region.
A highly developed infrastructure, an increase in healthcare expenditures, and the advancement of innovative therapies for the treatment of ringworm are some of the factors that are expected to boost the market in the forecast period. Approximately 9 Million outpatient visits and 75,000 hospitalizations are caused by fungal diseases every year. In addition, the region is focusing its efforts on developing innovative technologically advanced therapies to treat ringworms and prevent the spread of the disease, which will further grow the market over the coming years.
CDC data indicates that Dermatophyte infection-related outpatient visits, hospitalizations, and direct medical costs totaled 4,981,444 in 2020. Therefore, the region has seen an increase in treatment demand. From the above statements, it can be concluded that the North American region will hold a leading market share over the forecast period.
In recent years, the prevalence of these diseases has increased the demand for antifungal drugs, resulting in the development of fast-track FDA-approved antifungal treatments. The expansion of geographical reach and commercialization of pharmaceuticals by established companies are expected to contribute significantly to the growth of the regional market.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category Wise Insights
By Drug Class, Which Segment is Expected to Accelerate Sales of the Market?
Antifungal Drugs to Contribute to the Growth of the Ringworm Treatment Market
Increasing awareness about fungal infections is expected to contribute to the growth of the market in the coming years. A CAGR of 3.8% is predicted for the market during the forecast period. An increasing number of product launches, coupled with an increasing number of cases of fungal infections, are two of the major factors that are driving the revenue growth of the fungal infection market. In addition to increased tourism, global warming and a growing economy have all contributed to an increase in fungal illnesses treatments in the market.
A market share of 55% is expected to be achieved for antifungal drugs. Hospitalized patients with invasive fungal infections were much more likely to suffer from invasive fungal infections during the COVID-19 pandemic. In 2021, approximately 7,199 deaths due to fungal diseases were reported by the Centers for Disease Control and Prevention (CDC). Also, the availability of over-the-counter medications as well as the ease of administering ointments, oral pills, topical creams, and IV drips play a significant role in antifungal treatment demand.
As awareness increases among patients and healthcare professionals, the demand for this antifungal agent is expected to increase. Additionally, the lack of safe and effective antifungals available to treat ringworm infections has been identified as one of the primary factors driving growth during the forecast period. Although there are alternative treatments available for ringworm infections, such as herbal medicines, and a narrow market for antifungal drugs, the market for antifungals is expected to be limited.
How is the Topical Route of Administration Gaining Better Traction?
Topical Drugs to be the Most Promising Segment for Ringworm Treatment Market
Atopic treatments are expected to be the dominant form of treatment for ringworm in the coming years. Approximately 64% of the total market share for topical creams for the treatment of ringworm in the global market will be held by this market. In recent years, market demand for topical treatments has increased due to growing awareness about diseases and the availability of treatments that target the site of infection. As systemic side effects are reduced, treatment efficacy increases and patient compliance increases, revenue growth for this segment is expected to increase.
Due to their ease of use and effectiveness in treating ringworms, topical drugs are the most popular treatment segment for ringworm. As a result, there has been an increase in the availability of ringworm multiple topical anti-fungal drugs on the market, which is expected to contribute to the growth of the segment.
As well as providing relief from the symptoms of itching and burning associated with this condition, these creams can also affect the infection. As opposed to oral medications, topical medications don't enter the bloodstream. As an added benefit, topical drugs are more effective and cost-effective at treating localized ringworm infections. These factors have all contributed to the growth of the market in a positive way.
The Start-up Ecosystem: How will Startups Thrive in the Future?
Startups in the field of ringworm include the following:
- Zipnosis provides online diagnostics and treatment for a variety of medical conditions. Customers can use their smartphones or computers to diagnose and treat minor health problems. Simple acute medical conditions can be treated and triaged online through the platform. In addition to acne, influenza, and ringworm, patients can talk to doctors about a variety of other conditions. Approximately an hour after receiving a diagnosis, the company claims to be able to provide a treatment plan. Customers can also choose a pharmacy to receive prescriptions.
- Barrier Therapeutics develops topical drugs for dermatological disorders. As part of its product line, it offers Xolegel, a topical gel for the treatment of seborrheic dermatitis. Vision, for diaper dermatitis in infants and children, as well as Solage for lentigos. Additionally, the company developed Hyphanox for onychomycosis; Pramiconazole for fungal infections of the skin and mucosa, as well as Rambazole for the treatment of psoriasis. Stiefel Laboratories acquired the company in July 2008 for $148 Million.
Competitive Landscape
The key players in the global ringworm treatment market are conducting research and development activities to develop new products as well as antifungal ointments for the diagnosis and treatment of ringworms. These new treatments are anticipated to launch in the near future. Obtaining approval for new products in a timely manner gives companies a competitive edge over competitors.
- Bayer relaunches Canesten in the Indian market. Canesten cream, according to the company, helps treat fungal skin infections such as athlete's foot, ringworm, jock itch, and skin candidiasis. Further, the formulation is effective in treating vulvovaginal candidiasis complicated by inflammatory lesions and skin fungal infections.
- Close to 20,000 households will benefit from the Department of Health's program on herbal medicine, which was launched through the Philippine Institute of Traditional and Alternative Health Care. PITAHC developed HerbMAP under the supervision of Undersecretary Charade Mercado-Grande in response to the occurrence of the pandemic, which worsened the lack of herbal medications and products.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 8.38 Billion |
|
Market Value in 2033 |
US$ 13.91 Billion |
|
Growth Rate |
CAGR 5.2% |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018B to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Ringworm Treatment Market Industry Survey?
By Drug Class:
- Steroids
- Antifungals
- Anti-infective
- Others
By Route of Administration:
- Oral
- Topical
By Distribution Channel:
- Hospital Pharmacies
- Drug Stores
- Retailers
- E-commerce
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Frequently Asked Questions
FMI projects the global ringworm treatment market to expand at a CAGR of 5.2% by 2033.
The global ringworm treatment market is estimated at a market value of US$ 8.38 Billion.
The global ringworm treatment market is expected to garner a market value of US$ 13.91 Billion.
Asia Pacific is expected to experience a CAGR of 3.2% in the ringworm treatment market.
Perrigo Company plc, Novartis AG, GlaxoSmithKline Plc, Teva Pharmaceuticals, Inc., and Taro Pharmaceutical Industries Ltd. are some prominent ringworm treatment manufacturers in the market.
The antifungal market will hold 55% of the market value during the forecast period.
Table of Content
1. Executive Summary | Ringworm Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Steroids
5.3.2. Antifungals
5.3.3. Anti-infectives
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Topical
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Drug Stores
7.3.3. Retailers
7.3.4. E-commerce
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East & Africa
8.4. Market Attractiveness Analysis By Region
9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. Middle East & Africa Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MIDDLE EAST & AFRICA
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Analysis
14.1. United States
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class
14.1.2.2. By Route of Administration
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class
14.2.2.2. By Route of Administration
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class
14.3.2.2. By Route of Administration
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class
14.4.2.2. By Route of Administration
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class
14.5.2.2. By Route of Administration
14.5.2.3. By Distribution Channel
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class
14.6.2.2. By Route of Administration
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class
14.7.2.2. By Route of Administration
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class
14.8.2.2. By Route of Administration
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class
14.9.2.2. By Route of Administration
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class
14.10.2.2. By Route of Administration
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class
14.11.2.2. By Route of Administration
14.11.2.3. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class
14.12.2.2. By Route of Administration
14.12.2.3. By Distribution Channel
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class
14.13.2.2. By Route of Administration
14.13.2.3. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class
14.14.2.2. By Route of Administration
14.14.2.3. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class
14.15.2.2. By Route of Administration
14.15.2.3. By Distribution Channel
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Class
14.16.2.2. By Route of Administration
14.16.2.3. By Distribution Channel
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Class
14.17.2.2. By Route of Administration
14.17.2.3. By Distribution Channel
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Class
14.18.2.2. By Route of Administration
14.18.2.3. By Distribution Channel
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Class
14.19.2.2. By Route of Administration
14.19.2.3. By Distribution Channel
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Class
14.20.2.2. By Route of Administration
14.20.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Perrigo Company plc
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Novartis AG
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. GlaxoSmithKline plc
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Teva Pharmaceuticals, Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Taro Pharmaceutical Industries Ltd.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Glenmark Pharmaceuticals Inc.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Avik Pharma
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Actiza Pharmaceutical
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Chempro Group India
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Merck & Co., Inc.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Europe Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 17: Asia Pacific Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 19: Asia Pacific Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: Asia Pacific Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: MIDDLE EAST & AFRICA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: MIDDLE EAST & AFRICA Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: MIDDLE EAST & AFRICA Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: MIDDLE EAST & AFRICA Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 9: Global Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 10: Global Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 11: Global Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 15: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Attractiveness by Drug Class, 2023 to 2033
Figure 18: Global Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Attractiveness by Region, 2023 to 2033
Figure 21: North America Value (US$ Million) by Drug Class, 2023 to 2033
Figure 22: North America Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 24: North America Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 29: North America Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 30: North America Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Attractiveness by Drug Class, 2023 to 2033
Figure 38: North America Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Value (US$ Million) by Drug Class, 2023 to 2033
Figure 42: Latin America Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 49: Latin America Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 50: Latin America Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 51: Latin America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 55: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Attractiveness by Drug Class, 2023 to 2033
Figure 58: Latin America Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Attractiveness by Country, 2023 to 2033
Figure 61: Europe Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Europe Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 69: Europe Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Europe Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Europe Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 75: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Attractiveness by Drug Class, 2023 to 2033
Figure 78: Europe Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Value (US$ Million) by Drug Class, 2023 to 2033
Figure 82: Asia Pacific Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: Asia Pacific Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 84: Asia Pacific Value (US$ Million) by Country, 2023 to 2033
Figure 85: Asia Pacific Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 89: Asia Pacific Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 90: Asia Pacific Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 91: Asia Pacific Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: Asia Pacific Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: Asia Pacific Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: Asia Pacific Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 95: Asia Pacific Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: Asia Pacific Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: Asia Pacific Attractiveness by Drug Class, 2023 to 2033
Figure 98: Asia Pacific Attractiveness by Route of Administration, 2023 to 2033
Figure 99: Asia Pacific Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: Asia Pacific Attractiveness by Country, 2023 to 2033
Figure 101: MIDDLE EAST & AFRICA Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: MIDDLE EAST & AFRICA Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: MIDDLE EAST & AFRICA Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: MIDDLE EAST & AFRICA Value (US$ Million) by Country, 2023 to 2033
Figure 105: MIDDLE EAST & AFRICA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: MIDDLE EAST & AFRICA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: MIDDLE EAST & AFRICA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: MIDDLE EAST & AFRICA Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 109: MIDDLE EAST & AFRICA Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 110: MIDDLE EAST & AFRICA Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 111: MIDDLE EAST & AFRICA Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: MIDDLE EAST & AFRICA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: MIDDLE EAST & AFRICA Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: MIDDLE EAST & AFRICA Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 115: MIDDLE EAST & AFRICA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: MIDDLE EAST & AFRICA Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 117: MIDDLE EAST & AFRICA Attractiveness by Drug Class, 2023 to 2033
Figure 118: MIDDLE EAST & AFRICA Attractiveness by Route of Administration, 2023 to 2033
Figure 119: MIDDLE EAST & AFRICA Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: MIDDLE EAST & AFRICA Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
